Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients.
However, the majority don’t respond to immune therapy. Across different tumor types, pre-…

The activation of immune cells by targeting checkpoint inhibitors showed promising results
with increased patient survival in distinct primary cancers. Since only limited data exist for …

While the central nervous system is considered an immunoprivileged site and brain tumors
display immunosuppressive features, both innate and adaptive immune responses affect …

Tumor microenvironment-targeted therapies are emerging as promising treatment options for
different cancer types. Tumor-associated macrophages and microglia (TAMs) represent an …

The macrophage migration inhibitory factor ( MIF ) receptor CD 74 is overexpressed in various
neoplasms, mainly in hematologic tumors, and currently investigated in clinical studies. …

Background. Glioblastoma (GB) is incurable at present without established treatment options
for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and …

Background Brain metastases (BM) are a frequent complication of malignant melanoma (MM),
with limited treatment options and poor survival. Prevention of BM could be more effective …

Background Therapies based on targeting immune checkpoints have revolutionized the
treatment of metastatic melanoma in recent years. Still, biomarkers predicting long-term therapy …

The current World Health Organisation (WHO) Classification of Central Nervous System
Tumours defines oligodendrogliomas by IDH mutation and 1p/19q codeletion [12]. …

(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …